Human Health Portfolio NorthSea Therapeutics Bolsters Board, as Orziloben Moves into Late-stage Development März 31, 2026 PDF 270,6 KB Download
Human Health Portfolio NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD) Februar 21, 2024 PDF 186,0 KB Download
Human Health Portfolio NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease Oktober 17, 2023 PDF 199,1 KB Download
Human Health Portfolio NorthSea Therapeutics appoints Morris J. Birnbaum to the Board Dezember 21, 2022